USADA 2017 Annual Report / United States Anti-Doping Agency (USADA). - Colorado Springs : USADA, 2018

Dopingautoriteit Annual Report 2017 (Netherlands) / Anti-doping Authority Netherlands (Dopingautoriteit). - Capelle aan den IJssel : Dopingautoriteit, 2018

Contents:

Chapter 1 – Prevention
Chapter 2 – Therapeutic Use Exemptions
Chapter 3 – Doping control
Chapter 4 – Intelligence & Investigations
Chapter 5 – Disciplinary Proceedings
Chapter 6 – International Affairs
Chapter 7 – Legal Affairs
Chapter 8 – Scientific research
Chapter 9 – Knowledge management
Chapter 10 – People & organisation
--------------------------
Annex 1 - Financial overview
Annex 2 - Members of the Board of Management, Advisory Board and Committees
Annex 3 - Office staff
Annex 4 - Overview of doping control officials
Annex 5 - Overview of publications and presentations
Annex 6 - Secondary positions
Annex 7 - Abbreviations

Results of the WADA monitoring program regarding substances which are not on the 2017 Prohibited List, but which WADA wishes to monitor in order to detect patterns of misuse in sport.

These substances are:

In Competition Monitoring:
- Mitragynine
- Tramadol
- Codeine

In and Out of Competition Monitoring:
- Telmisartan
- Glucocorticoids
- Beta-2 Agonists

Ethical aspects of doping and anti-doping : in search of an alternative policy / Bengt Kayser. - Catholic University of Leuven (KU Leuven), 2018. - Dissertation KU Leuven presented in partial fulfillment of the requirements for the degree of Doctor in Kinesiology.
- With summary in Dutch: p. ix - xii

Abstract:

The general aim of this thesis is to contribute to the discussion on doping and anti-doping, and to sketch the outlines of an alternative way of dealing with doping inside and outside of sport. After a short introduction (Chapter 1) that sketches the historical background of the main issues, an analysis of modern anti-doping in elite sport is presented, highlighting some paradoxes and weaknesses at the basis of today’s anti-doping policies (Chapter 2). Chapter 3 provides an analysis of the argument that allowing doping would merely result in a uniform shift of the playing field at the cost of greater health risks. It is shown that this is unlikely to be the case and a counterargument in favour of allowing some regulated forms of doping, because potentially leading to a more dynamic playing field, is then presented. Chapter 4 provides a perspective accounting for some of the side effects of modern anti-doping, also from a legal perspective. It highlights some of these side-effects and shows that anti-doping comes at a considerable cost to the individual athlete and the community. Chapter 5 then introduces the idea of using a harm reduction approach in the realm of doping in sport. First the principle of harm reduction is explained, building upon the evidence base in the field of recreational substance use. This is followed by a first attempt of applying its principles to doping practices in sport. Chapter 6 then takes the reasoning of the preceding chapter further by completing it with a specific analysis of the ethical implications of such a harm reduction approach for doping, concluding that such an approach can be defended. Chapter 7 finally provides a general discussion that ends with some conclusions and perspectives. The overarching conclusion of the thesis is that there is no society-wide solution to the problem of doping. Therefore practical ways of dealing with its presence aimed at containing its potential risks may represent preferable policy alternatives as compared to today’s runaway effects of globalisation of anti-doping efforts, all while promising to enrich the spectacle of modern elite sport.

Contents:

1.) Introductory remarks
2.) Current anti-doping policy: a critical appraisal
3.) What if we relaxed the anti-doping rule: towards a Red Queen effect?
4.) On the presumption of guilt without proof of intentionality and other consequences of current anti-doping policy
5.) Doping and performance enhancement: harms and harm reduction
6.) Ethics of a relaxed anti-doping rule accompanied by harm-reduction measures
7.) Discussion, conclusions and perspectives
- Appositions
- Short CV
- Publications on doping and anti-doping
- Acknowledgements, Personal contributions, Conflict of interest statement
A.) French speaking athletes’ experience and perception regarding the whereabouts reporting system and therapeutic use exemptions
B.) The anti-doping industry coming of age: in search of new markets
C.) Do public perception and the ‘spirit of sport’ justify the criminalisation of doping? A reply to Claire Sumner

Årsrapport 2017 Stiftelsen Antidoping Norge / Antidoping Norge (ADNO). - Oslo : ADNO, 2018

NADA Annual Report 2017 / National Anti Doping Agency of Germany. - Bonn : Nationale Anti Doping Agentur Deutschland (NADA), 2018
NADA Material No. 63

2016 Anti-Doping Rule Violations (ADRVs) Report / World Anti-Doping Agency (WADA). - Montreal : WADA, 2018.
- Report compiled based on cases received by WADA before 31 December 2017

This is the fourth year that WADA publishes the ADRVs Report. The Report illustrates doping offences committed under the World Anti-Doping Code in 2016.

The Report includes the decisions of all adverse analytical findings (AAFs) for which the samples were collected by anti-doping organizations (ADOs) in 2016 and the results are reported in ADAMS as well as non-analytical anti-doping rule violations for decisions rendered in 2016. Discrepancy from ADOs’ published statistics may occur due to different reporting criteria.

The ADRVs Report is broken down as follows:

• An Introduction and an Executive Summary, which provide an overview of the Report and highlight the key observations of the 2016 ADRVs Report.
• Sections 1 and 2 present the results management outcomes (including ADRVs) of all AAFs detected by WADA-accredited Laboratories for samples collected from athletes in- and out-of-competition in 2016. They are presented by sport, discipline (Section 1) and testing authority (Section 2).
• Section 3 includes ADRVs that resulted from non-analytical findings committed by athletes (presented by sport and nationality) and by athlete support personnel (presented by nationality).
• Section 4 indicates the total number of ADRVs from athletes in 2016, which includes AAFs that resulted in an ADRV plus all non-analytical ADRVs. The data is presented by sport and nationality. The information is further broken down into type of samples (urine or blood), type of test (in- or out-of-competition) and athlete gender.

Contents:

Introduction
Executive Summary
Section 1: Outcomes of 2016 AAFs by Sport Category
Section 2: Outcomes of 2016 AAFs by Testing Authority Category
Section 3: Report of 2016 Non-Analytical ADRVs
Section 4: Report of 20165 Total Analytical and Non-Analytical ADRVs

Related case:
ISR 2017 KNBSB Decision Disciplinary Committee 2017011 T
December 22, 2017

On 22 December 2017 the ISR Disciplinary Committee of the Royal Dutch Baseball and Softball Federation (KNBSB) decided to impose a 4 year period of ineligibility on the Person after he tested positive for the prohibited substance Dehydrochlormethyltestosterone. The Person didn’t file a statement in his defence nor did he request for a hearing. An alleged supplement was tested but the laboratory analysis revealed no prohibited substances.

Hereafter in February 2018 the Person appealed the decision of 22 December 2017 with the ISR-KNBSB Appeal Committee. The Person argued that the anti-doping violation was not intentional and he raised the hypothesis that someone put the substance in his drink.

The Appeal Committee finds that the Person failed to produce any evidence in support of his argument and hypothesis. Neither did he establish how the prohibited substance entered his system. The Person’s claim about his unfamiliarity with the anti-doping rules is rejected.

Therefore The ISR-KNBSB Appeal Committee decides on 18 April 2018 to dismiss the Person’s appeal and to uphold the ISR-KNBSB decision of 22 December 2018.

Fees and expenses for this committee shall be borne by the Person.